Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs Houston, TX

Marker Therapeutics Appoints Nadia Agopyan,

Vice President of Regulatory Affairs

Houston, TX - August 15, 2019 - Marker

Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation

T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the

appointment of Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs, effective August 15.

"We are pleased to welcome a professional of Nadia's

caliber and senior leadership experience to Marker," said Peter L. Hoang, President & CEO of Marker. "With more

than 15 years of industry knowledge in regulatory affairs and clinical development, Nadia will be instrumental in helping shape

our regulatory strategy as we prepare to initiate the first Marker-sponsored trial with MultiTAA therapy in patients with post-transplant

acute myeloid leukemia."

Dr. Agopyan joins Marker from Kite Pharma, a subsidiary of Gilead

Sciences, where she served as Director of Regulatory Affairs, Global Regulatory Lead. In this role, she was responsible for overseeing

the global marketing authorization and lifecycle management of the YESCARTA franchise, defining the global regulatory strategies

for CAR T cell products in lymphoma/leukemia, and overseeing clinical programs from Phase 1-4 development, as well as all operational

aspects of global regulatory submissions. Previously, she served as Global Regulatory Lead at Baxter Biosciences leading Vonvendi

(recombinant von Willebrand Factor) approval/launch, Senior Director Regulatory Affairs at Ambit Biosciences, and Director Regulatory

Affairs at Cougar Biotechnology, a unit of Johnson and Johnson Ortho Biotech Oncology, where she led the approval of Zytiga, abiraterone

acetate, for the treatment of patients with metastatic castrate-resistant prostate cancer.

Earlier in her career, Dr. Agopyan served in various roles at

biotechnology companies such as Amgen, CATO Research and Allelix Biopharmaceuticals and as Assistant Professor in academia including

Duke University and University of Toronto.

Dr. Agopyan earned her Ph.D. and B.Sc. in Neurophysiology from

McGill University (Montreal Canada).

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology

company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies

and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific

T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population

of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune

system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe

that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered

CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio

of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative peptide- and

gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200)

for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical trials.

To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/

Forward-Looking Statement Disclaimer

This release contains forward-looking statements for

purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release

concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning

assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking

statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses

or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating

to our non-engineered multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs; the effectiveness of

these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and,

the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking statements

are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from

those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the

Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company

assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise,

after the date of this press release.